Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 6/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150133 | 0.80 | BACE1 (0.57) | BACE1CYP3A4BLMXDHPOLB | |
| SCHEMBL5907152 | 0.74 | BACE1 (0.74) | BACE1CYP3A4BLMXDHPOLB | |
| SCHEMBL4143300 | 0.73 | BACE1 (0.53) | BACE1CYP3A4BLMXDHPOLB | |
| SCHEMBL4143461 | 0.72 | BACE1 (0.56) | BACE1KDM4E | |
| SCHEMBL4142794 | 0.71 | BACE1 (0.73) | BACE1CYP3A4BLMXDHABL1 | |
| SCHEMBL4136769 | 0.70 | BACE1 (0.72) | BACE1CYP3A4BLMXDH | |
| SCHEMBL6068586 | 0.69 | POLB (0.55) | BACE1CYP3A4BLMXDHPOLB | |
| SCHEMBL13914840 | 0.69 | BACE1 (0.57) | BACE1CYP3A4BLMXDHPOLB | |
| SCHEMBL2403638 | 0.68 | BACE1 (0.73) | BACE1CYP3A4BLMXDHPOLB | |
| SCHEMBL10617521 | 0.68 | BACE1 (0.62) | BACE1CYP3A4BLMXDHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1802587-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | BACE1 3/4885CYP3A4 2100/4885BLM 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.